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Among the many challenges facing
institutional review boards (IRBs) is to
predict whether the activities and inter-
ventions proposed in a clinical trial
protocol are likely to yield net harm or
net benefit for trial participants. IRBs take
these questions very seriously, and never
more so than in the review of first-in-
human (FIH) trials, where interpreting
findings about risks to humans from
animal data requires a leap of faith,
regardless of the quality of the available
data.
In their paper published this week in
PLoS Medicine [1], ‘‘Predicting harms and
benefits in translational trials: Ethics,
evidence, and uncertainty,’’ Jonathan
Kimmelman and Alex London argue that
decision-makers (which, from the context
of their paper, I assume to mean IRB
members) pay insufficient attention to
threats to validity in preclinical studies
and consult too narrow a set of evidence,
thereby unnecessarily limiting predictions
about risks and potential benefits for
humans that they might otherwise be able
to make. They advocate greater attention
to the quality of preclinical evidence and
to research on related agents. These
strategies are meant to reduce what they
call the ‘‘misestimation’’ of risks or antic-
ipated benefits, which they argue ‘‘threat-
ens the integrity of the scientific enterprise,
because it frustrates prudent allocation of
research resources’’[1].
Kimmelman and London’s proposal is
likely to stimulate a great deal of construc-
tive debate among clinical trialists, regu-
lators, and other members of the research
ethics community. In my brief comments
here, I will attempt to open this debate by
identifying a key aspect of their proposal
that is likely to generate particular interest
and perhaps even some controversy—that
is, their framing of the problem in terms of
how effectively decision-makers utilize
evidence from preclinical or animal stud-
ies. Although IRB members often do not
have deep grounding in the subtleties of
research design and inferential statistics, it
would be wrong to suggest that ‘‘misesti-
mation’’ of risk and potential benefit arises
solely from errors by IRB members (or
other decision-makers).
Misestimates of Risk
There is no doubt that IRB members
may ‘‘misestimate’’ risk and benefit, in the
sense that they may draw erroneous
conclusions about the transferability of
findings from animal studies to human
studies. But it is equally likely that it may
often be impossible (or infeasible) to
determine when (if ever) the inferences
arising from animal studies are truly valid,
in the multiple senses suggested. Internal
and construct validity, for example, both
rely to some degree on the accuracy of the
underlying theory, i.e., whether it properly
accounts for the relevant mechanisms of
action. To understand the dilemma, one
need only consider the large number of
drugs that are approved for use by
regulatory authorities on the basis of some
demonstration of efficacy and safety, but
whose mechanisms of actions are still
unknown or have been poorly understood
for many years after approval (e.g.,
acetominophen, GABA). This issue be-
comes particularly important in light of
Kimmelman and London’s proposal to
systematize the assessment of preclinical
studies from reference classes of com-
pounds as part of the routine due diligence
of assessing risk and potential benefit in
first in human trials.
The most pressing problem is one of
completeness, a specific dimension of
construct validity: do the theory and data
account for all the relevant elements or
mechanisms that might contribute to
benefit or harm in humans? This is the
‘‘black swan’’ or ‘‘unknown unknowns’’
problem in FIH trials: What molecular
landmines lie beyond our current data or
imagination?
The Black Swan
The widely reported TGN1412 trials in
the UK [2] may provide an instructive test
case for Kimmelman and London’s pro-
posal. Six healthy volunteers were given
the test agent, TGN1412 (an immune
modulator), which triggered a cytokine
storm and subsequent multiple organ
failure, even at a fraction of the dose
found to be safe in macaque monkeys [2].
Kimmelman and London’s proposal could
have been useful, in principle, in the
TGN1412 trial in that it would have
required reviewers to question whether
the animal models truly are sufficiently
similar to the relevant human systems to
permit the right kind of conclusions about
safety and potential benefits in humans.
One theory about the TGN1412 trials [3]
is that the catastrophic effects were
mediated by memory B cells, which may
have been absent or under-developed in
the laboratory animals. The animal data,
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in that critical sense. Whether or not this
specific theory is correct, it serves well to
illustrate that this is not an insight that
arises from the animal data themselves. It
is a deeper question—precisely the kind
that Kimmelman and London are encour-
aging IRB members to ask, but one for
which there may be no obvious trigger.
The central shortcoming in construct
validity is likely to remain a ‘‘black swan’’
until scrutiny or experience reveals it.
A Valuable Proposal
Kimmelman and London’s proposal is
valuable precisely because it encourages
IRB members, and other reviewers, to
engage with less-familiar challenges and
guard against complacency in reviewing
risk and benefit data from preclinical
studies. But its true potential value likely
lies in the extent to which it can forge
agreement throughout the research enter-
prise on the need for more creative
approaches to presenting and contextual-
izing preclinical evidence, and on broad-
ening the base of responsibility for these
difficult judgments.
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